Literature DB >> 16583210

Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases.

Takeshi Echigo1, Minoru Hasegawa, Yuka Shimada, Makoto Inaoki, Kazuhiko Takehara, Shinichi Sato.   

Abstract

Although chemokines are critical elements for the selective attraction and activation of various leukocyte subsets in the inflammatory process, there are few findings concerning T helper (Th) 1 or Th2 chemokines in autoimmune blistering disease (ABD). To determine whether serum levels of chemokines that are preferentially chemotactic for Th1 (monokine induced by IFN-gamma (MIG/CXCL9)) and Th2 (thymus and activation regulated chemokine (TARC/CCL17) and macrophage derived chemokine (MDC/CCL22)) cells were elevated and whether they correlated with the clinical features in patients with ABD. Serum chemokine levels were examined using ELISA in patients with pemphigus vulgaris (PV, n=19), pemphigus foliaceous (PF, n=14), or bullous pemphigoid (BP, n=27) and normal controls (n=20). Serum MIG levels were significantly higher in patients with PV, PF, or BP than those in the control subjects. Serum levels of TARC and MDC were also significantly elevated in patients with PV, PF, or BP relative to the normal controls. Among the ABD subgroups, the levels of each chemokine tended to be higher in BP patients than in PV patients. Furthermore, serum TARC levels correlated positively with serum IgE levels in patients with ABD. Levels of TARC, MDC, and MIG were significantly decreased after treatment when the skin lesions disappeared in these patients. Furthermore, serum MIG levels correlated positively with serum levels of TARC and MDC in the ABD patients. These results suggest that both a Th1 chemoattractant MIG and Th2 chemoattractants, TARC and MDC, cooperatively play a role in the development of ABD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16583210     DOI: 10.1007/s00403-006-0661-5

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  7 in total

Review 1.  Immune response in pemphigus and beyond: progresses and emerging concepts.

Authors:  Giovanni Di Zenzo; Kyle T Amber; Beyza S Sayar; Eliane J Müller; Luca Borradori
Journal:  Semin Immunopathol       Date:  2015-11-23       Impact factor: 9.623

2.  CCR4 agonists CCL22 and CCL17 are elevated in pediatric OMS sera: rapid and selective down-regulation of CCL22 by ACTH or corticosteroids.

Authors:  Michael R Pranzatelli; Elizabeth D Tate; Nathan R McGee; Jerry A Colliver; Richard M Ransohoff
Journal:  J Clin Immunol       Date:  2013-01-23       Impact factor: 8.317

3.  Vitamin D and skeletal health in autoimmune bullous skin diseases: a case control study.

Authors:  Angelo Valerio Marzano; Valentina Trevisan; Elisa Cairoli; Cristina Eller-Vainicher; Valentina Morelli; Anna Spada; Carlo Crosti; Iacopo Chiodini
Journal:  Orphanet J Rare Dis       Date:  2015-02-03       Impact factor: 4.123

4.  Th1/Th17-Related Cytokines and Chemokines and Their Implications in the Pathogenesis of Pemphigus Vulgaris.

Authors:  Rodolfo Pessato Timoteo; Marcos Vinicius da Silva; Camila Botelho Miguel; Djalma Alexandre Alves Silva; Jonatas Da Silva Catarino; Virmondes Rodrigues Junior; Helioswilton Sales-Campos; Carlo Jose Freire Oliveira
Journal:  Mediators Inflamm       Date:  2017-02-22       Impact factor: 4.711

Review 5.  Pemphigus: Current and Future Therapeutic Strategies.

Authors:  Dario Didona; Roberto Maglie; Rüdiger Eming; Michael Hertl
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

6.  Activation of Blood Coagulation in Two Prototypic Autoimmune Skin Diseases: A Possible Link with Thrombotic Risk.

Authors:  Massimo Cugno; Alberto Tedeschi; Alessandro Borghi; Paolo Bucciarelli; Riccardo Asero; Luigia Venegoni; Samantha Griffini; Elena Grovetti; Emilio Berti; Angelo Valerio Marzano
Journal:  PLoS One       Date:  2015-06-09       Impact factor: 3.240

Review 7.  Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid.

Authors:  Tong Zhou; Bin Peng; Songmei Geng
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.